Topic Listing for Idenix Pharmaceuticals

Adjustments Changes Common Stock Certain Other Events Administration
Administration Delegation Agreements Grant Exclusive Right Make Sell Drug Candidates
Agreements Grant Exclusive Right Make Sell Product Candidates Amendment
Annual Cash Incentive Bonus Annual Cash Performance Incentives
Annual Stock Option Awards Antiviral Research
Asia Audit Committee Report
Available Information Award Limits
Awards Background
Base Salary Because Limited Sales Marketing Distribution Capabilities Seek Enter
Beneficial Ownership Reporting Compliance Benefits
Board Directors Breach Numerous Representations Warranties Novartis Development Agreement Stock
Breach Numerous Representations Warranties Novartis Development Commercialization Agreement Budget Payment Schedule
Business Substantial Risk Product Liability Claims Unable Obtain Cambridge 8211 2009
Cambridge Mass 2009 Cash Equivalents
Cash Signing Bonus Cash Signing Bonuses
Cautionary Statement Regarding Forward-looking Statements Centre National Recherche Scientifique Luniversite Montpellier
Certain Effects Proposed Amendment Certificate Amendment Restated Incorporation Idenix Pharmaceuticals Inc
Change Control Payments Change-in-control Payments
Changes Internal Control Over Financial Reporting Clinical Trials Not Successful Obtain Regulatory Approval Commercial
Cnrs University Montpellier Co-operative Laboratory Agreements
Codes Business Conduct Collaboration License Agreements
Collaborations Outside Scientists Subject Restriction Change Collaborative Partner Terminates Fails Perform Obligations Agreements Development
Collaborative Research Development Revenue Commercial Markets Intend Enter Subject Intense Competition Unable
Committees Board Directors Communicating Board Directors
Comparison 2005 2004 Comparison 2006 2005
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Summary Competition
Components Executive Compensation Program Comprehensive Income Loss
Comprehensive Loss Concentration Credit Risk
Confidentiality Agreements Employees Others Not Adequately Prevent Disclosure Continue Evolve Was Primarily Involved Discovery Development Also
Cooperative Laboratory Agreements Cooperative Research Agreement University Cagliari Terminated Breach Unable
Cooperative Research Agreement University Cagliari Terminated Unable Utilize Corporate Governance Guidelines
Corporate Objectives Cost Sales
Currently Depend Novartis Significant Portion Revenues Commercialization Tyzeka Data Protection
Depend Third-party Manufacturers Manufacture Products Future Required Incur Depended Third-party Manufacturers Manufacture Products Future Required Incur
Description Awards Designated Contact Persons Key Personnel
Designation Products Determination Stock Option Exercise Prices
Development Commercialization Agreement Development License Commercialization Agreement
Development Products Regulatory Activities Developments
Director Attendance Annual Meetings Stockholders Director Compensation
Director Independence Director Qualification Standards
Disclosure Controls Procedures Dividends
Documents Incorporated Reference Drug Candidates Development Remain Subject Clinical Testing Regulatory
Drug Candidates Fail Obtain Foreign Regulatory Approval Partners Effective Date Amendment Expiration
Eligibility Eligibility Receive Awards
Employees Employment Agreements
Equity Compensation Plan Information Equity Compensation Table
Estimates Assumptions Estimates Make Assumptions Rely Preparing Financial Statements Prove
Europe Evaluation Disclosure Controls Procedures
Exact Name Registrant Specified Charter Exclusivity
Executive Compensation Executive Officers
Executive Summary Factors Related Common Stock
Factors Related Dependence Parties Fail Comply Ongoing Regulatory Requirements After Receipt Approval
Fail Design Maintain Effective System Internal Controls Not Failure Successfully Acquire Develop Market Additional Drug Candidates
Failure Successfully Acquire Develop Market Additional Product Candidates Fair Value Financial Instruments
Federal Income Tax Consequences Fluctuation Quarterly Results Cause Stock Price Decline Resulting
Foreign Currency Foreign Currency Exchange Rate Risk
Foreign Jurisdictions Foreign Regulation Drug Product Approval
Form 10-k Gain Sale Equity Securities
General Provisions Applicable Awards Glaxosmithkline Collaboration
Grants Plan-based Awards Gsk Collaboration
Hazardous Materials Hbv
Hcv Hcv Discovery Program
Hepatitis Hepatitis Drug Candidates
Hepatitis Patent Portfolio Hepatitis Patent Portfolio Licenses
Hepatitis Product Hepatitis Product Candidates
Hiv Hiv Patent Portfolio
Householding Annual Meeting Materials Idenix Pharmaceuticals Inc
Impairment Long-lived Assets Income Taxes
Indemnification Information Nominating Process
Initial New Hire Grant Initial New Hire Stock Option Grant
Initial Public Offering Common Stock Insurance Policies Expensive Protect Only Some Business Risks
Intangible Asset Interest Rate Risk
Interferon Products Inventory
Investment Investment Common Stock Decline Value Result Announcements Business
Investment Income Net Investment Other Income Net
Investments Subject General Credit Liquidity Market Interest Rate Issue Capital Stock Certain Situations Novartis Able Purchase
Lease Arrangements Legal Contingencies
Legal Proceeding Involving Director Legal Representative
License Agreement Gsk Important Business Royalties Other Payments Licensing Agreements
Limited Operating History Incurred Cumulative Loss Since Inception Managements Annual Report Internal Control Over Financial Reporting
Manufacturing Manufacturing Packaging Agreements
Market Information Marketable Securities
Marketing Applications Format Markets Intend Enter Subject Intense Competition Unable Compete
Master Manufacturing Supply Agreement Materially Breach Obligations Covenants Arising Development Commercialization Agreement
Meetings Independent Directors Microbiologica Quimica Farmaceutica Ltda
Miscellaneous Net Income Loss Per Common Share
Net Loss Per Common Share Not Able Attract Retain Key Management Scientific Commercial
Not Able Attract Retain Key Management Scientific Personnel Not Able Continue Commercialize Drug Products Successfully Unable
Not Comply Laws Regulating Protection Environment Health Human Notice 2007 Annual Meeting Stockholders
Notice 2008 Annual Meeting Stockholders Notice 2009 Annual Meeting Stockholders
Novartis Collaboration Novartis Option License Drug Candidates Discover Some Cases
Novartis Right Certain Circumstances Market Sell Products Compete Novartis Right Exercise Control Over Certain Corporate Actions
Novartis Right Market Sell Products Compete Drug Candidates Novartis Stock Purchase Rights
Novartis Substantial Control Over Delay Prevent Change Corporate Novartis Terminates Fails Perform Obligations Development Commercialization Agreement
Novartiss Ability Maintain Percentage Ownership Interest Novartiss Ability Maintain Percentage Ownership Interest Capital Stock
Now Therefore Objectives Philosophy Compensation Program
Option Exercises Stock Vested Other Information
Other Matters Other Stock-based Awards
Outstanding Equity Awards Year-end Overview
Overview Director Compensation Overview Philosophy Procedures Determining Executive Compensation
Overview Process Procedures Determining Executive Compensation Page Inserted After Proxy Finalized
Part Partners Fail Comply Ongoing Regulatory Requirements After Receipt
Patents Patents Licenses
Pharmaceutical Pricing Reimbursement Pharmaceutical Research Associates Inc
Phase Clinical Trials Nda Phase Iiib Clinical Trials
Policies Procedures Related Person Transactions Policy Business Conduct Ethics
Potential Change Control Payments Potential Payments Termination Change Control
Potential Termination Payments Pre-approval Policies Procedures
Principal Accountant Fees Services Principal Accounting Fees Services
Principles Consolidation Product Candidates Development Remain Subject Clinical Testing Regulatory
Product Candidates Fail Obtain Foreign Regulatory Approval Collaborators Product Candidates Fail Obtain Foreign Regulatory Approval Partners
Product Commercialization Products Drug Candidates
Products Product Candidates Products Subject Ongoing Regulatory Review Even After Approval
Project Schedule Project Specifications
Property Equipment Proposal Amendment Restated Certificate Incorporation
Proposal Election Directors Proposal Ratification Selection Independent Registered Public Accounting Firm
Proxies Voting Purpose
Ratification Balance Agreement Reasons Increase Authorized Stock
Recent Accounting Pronouncements Registrants Telephone Number Including Area Code
Registration Rights Relationship Novartis Pharma
Relocation Reorganization Event
Report Independent Registered Public Accounting Firm Research Development Efforts Not Result Additional Drug Candidates
Research Development Efforts Not Result Additional Product Candidates Research Development Expenses
Restricted Stock Units Restructuring Impairment Charges
Revenue Recognition Revenues
Review Managements Actual Performance Compared Pre-determined Goals Sales Additional Shares Common Stock Result Dilution Existing
Sales Marketing Seek Enter Collaboration Agreements Drug Candidates Other Those
Seek Enter Collaboration Agreements Product Candidates Other Those Segment Reporting
Selling General Administrative Expenses Severance Change Control Benefits
Severance Change-in-control Benefits Severance Payments
Share-based Compensation Shares Subject Plan
Signatures Stock Appreciation Rights
Stock Available Awards Stock Option Awards
Stock Option Grant Practices Stock Option Grants
Stock Option Grants 2008 Stock Options
Stock Purchase Agreement Stock-based Compensation
Stockholder Proposals 2008 Annual Meeting Stockholders
Stockholders Agreement Subject Class Action Litigation Due Stock Price Volatility
Subject Unfavorable Pricing Regulations Third-party Reimbursement Practices Healthcare Sumitomo Pharmaceuticals Ltd
Summary Summary Description 2005 Stock Incentive Plan
Table Contents Tax Considerations
Termination Transition Novartis
Uab Research Foundation Unable Commercialize Products Receive Approval Regulatory Agencies
Universita Cagliari University Cagliari
Valopicitabine Valtorcitabine
Valuation Impairment Investments Marketable Securities Violate Healthcare Statutes Such Fraud Abuse Laws Subject
Whereas Witness Whereof
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki